Manitoba
Health, Seniors and Long-Term Care

Vaccine Clinic Resource for Immunizers

Disclaimer: *this Quick Reference is not intended to replace other product specific vaccine references. The document is intended as a quick reference for frequently referred to information. Please refer to the product monograph and vaccine specific resources for all current and complete information.*

Title:	**Mpox Vaccine (IMVAMUNE®) Quick Reference Guide** ***IMVAMUNE® vaccine is indicated for active immunization against smallpox, mpox and related orthopoxvirus infection for those 18 years of age or older at high risk of infection***
Effective Date:	September 11, 2024
Approver:	Final

Mpox Vaccine Resources:

Fact sheet
Mpox vaccine factsheet

Product Monograph
https://pdf.hres.ca/dpd_pm/00071931.PDF

Eligibility Criteria
For the most up to date information on eligibility criteria refer to www.gov.mb.ca/health/publichealth/diseases/mpox.html

NACI – Interim Guidance on the use of Imvamune®
https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/guidance-imvamune-monkeypox/guidance-imvamune-monkeypox-en.pdf

Canadian Immunization Guide:
For additional guidance on contraindications, precautions and special populations refer to the vaccine specific section:
https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-21-smallpox-vaccine.html

Manitoba
Health, Seniors and Long-Term Care

Mpox Vaccine

Product	Storage and Handling	Mpox Eligibility Criteria	Recommendations for Use

IMVAMUNE®
Modified Vaccinia Ankara-Bavarian Nordic® (live-attenuated, non-replicating) *
 	
Format:
Single or 10/per box
0.5 ml vials
 	
Product is latex, preservative and adjuvant free.
Potential Allergens: Benzonase, gentamicin and ciprofloxacin
Other Ingredients: Tris-hydroxymethyl-amino methane, sodium chloride, hydrochloric acid, trometamol
 	
*****_Imvamune®, 3rd generation orthopoxvirus vaccine, is labelled as JYNNEOS® and Imvanex® in other jurisdictions. These vaccines are also considered valid when assessing previous vaccination status._
	Storage:
	Store frozen at -20°C ± 5°C or -50°C ± 10°C or -80°C ± 10°C. Expiry date depends on storage temperature
	
	Thaw at room temperature. After thawing, the vaccine can be stored at 2°C – 8°C for up to 2 months prior to use.
	
	Do not refreeze a vial once it has been thawed.
	
	Protect from light.
	
	Handling:
	After thawing, the drug product should appear as a pale milky colored homogeneous suspension. The liquid vaccine should be visually inspected for any foreign particulate matter prior to administration.
		Pre-exposure prophylaxis (PrEP):
		
		• cisgender, transgender, or two-spirit people who self-identify as belonging to the gay, bisexual and other men who have sex with men (gbMSM) community and who meet at least one of the following criteria:
		  ◦ have received a diagnosis of a sexually transmitted infection in the past year;
		  ◦ have had two or more sexual partners in the past 90 days;
		  ◦ have attended locations for sexual contact (e.g. bath houses or sex clubs) or are planning to;
		  ◦ have had anonymous sex in the past 90 days (i.e. using apps, online sites, formal/informal gatherings) or are planning to;
		  ◦ engaged in sex work or plan to, as a worker or client; or
		• any sexual contacts of the individuals described above.
		• individuals who self-identify as sex workers, regardless of self-identified sex/gender
		• staff or volunteers in sex-on-premises venues where workers may have contact with objects or materials that may be contaminated with the mpox virus without the use of personal protective equipment
		• individuals who engage in sex tourism regardless of gender, sex assigned at birth, or sexual orientation
		• individuals who anticipate experiencing any of the above scenarios
		
		For the most current eligibility criteria refer to:
		www.gov.mb.ca/health/publichealth/diseases/mpox.html
			Pre-exposure prophylaxis (PrEP): 2 doses
			
			Interval: 28 days (4 weeks) apart*
			
			Dosage: 0.5 ml
			
			Route: SC (5/8” 25g needle)
			
			*28 days is the minimum/preferred interval. 2nd dose can be given later than 28 days to complete the series
			
			➢ Imvamune can be administered concurrently (i.e., same day) or at any time before or after live or non-live vaccines.
			
			➢ Imvamune® may be offered to the following populations if vaccination is recommended based on high-risk criteria:
			
			  ◦ Individuals who are immunocompromised due to disease or treatment
			  ◦ Individuals who are pregnant
			  ◦ Individuals who are lactating/breastfeeding
			  ◦ Children and youth (< 18 years of age)

Mpox Vaccine

Product	Storage and Handling	Mpox Eligibility Criteria	Recommendations for Use
IMVAMUNE® Modified Vaccinia Ankara-Bavarian Nordic® (live-attenuated, non-replicating) * **Format:** Single or 10/per box 0.5 ml vials Product is latex, preservative and adjuvant free. **Potential Allergens:** Benzonase, gentamicin and ciprofloxacin ***Other Ingredients:*** Tris-hydroxymethyl-amino methane, sodium chloride, hydrochloric acid, trometamol *****_Imvamune®, 3rd generation orthopoxvirus vaccine, is labelled as JYNNEOS® and Imvanex® in other jurisdictions. These vaccines are also considered valid when assessing previous vaccination status._	**Storage:** Store frozen at -20°C ± 5°C or -50°C ± 10°C or -80°C ± 10°C. Expiry date depends on storage temperature Thaw at room temperature. After thawing, the vaccine can be stored at 2°C – 8°C for up to 2 months prior to use. Do not refreeze a vial once it has been thawed. Protect from light. **Handling:** After thawing, the drug product should appear as a pale milky colored homogeneous suspension. The liquid vaccine should be visually inspected for any foreign particulate matter prior to administration.	**Post-exposure prophylaxis (PEP):** High risk close contacts of a confirmed or probable mpox case. * • **Previously unimmunized with Imvamune®** Since we do not know the effectiveness of the previous generations of smallpox vaccination against current mpox infection, all individuals who received previous generations of smallpox vaccine, as well as unimmunized individuals, should receive 1 dose of Imvamune® for PEP if they have been exposed to a probable or confirmed case of mpox. If the person also meets eligibility criteria for PrEP, a second dose of Imvamune® should be offered for administration 28 days later. • **1 previous dose of Imvamune®** For contacts that previously received one dose of Imvamune® prior to exposure to a confirmed or probable case, 1 dose of Imvamune® should be administered for PEP if it has been at least 28 days since the pre-exposure dose was received. • **2 previous doses of Imvamune®** Consider contact as fully immunized and no PEP required. *For further information on contacts and PEP refer to the Mpox (Orthopoxvirus) Protocol	**Post-exposure prophylaxis (PEP):** 1 or 2 doses **Interval:** • 1st dose preferably to be given 0-4 days after last exposure or up to 14 days after last exposure* • 2nd dose given 28 days (4 weeks) apart** **Dosage:** 0.5 ml **Route:** SC (5/8” 25g needle) * Vaccine should be given within 4 days from the date of exposure to prevent onset of the disease. However, vaccine can be given up to 14 days after the date of exposure, and may reduce the symptoms of disease, but may not prevent the disease. **28 days is the minimum/preferred interval. 2nd dose can be given later than 28 days to complete the series ➢ Imvamune® can be administered concurrently (i.e., same day) or at any time before or after live or non-live vaccines. ➢ Imvamune® may be offered to the following populations if vaccination is recommended based on high-risk criteria: ○ Individuals who are immunocompromised due to disease or treatment ○ Individuals who are pregnant ○ Individuals who are lactating/breastfeeding ○ Children and youth (< 18 years of age)